| HOME >> BIOLOGY >> TECHNOLOGY |
WOBURN, Mass., April 30 /PRNewswire/ -- AstraZeneca, Eli Lilly and Rx Canada received top honors at the 2008 Strategic Patient Adherence (SPA) Awards. Rx Canada and their client (AstraZeneca Canada), the first international award winners, received awards for the Best Branded Compliance Program. The Health Inform(R) Programs for Crestor, Symbicort and Nexium medications were lauded for measurement of each program's effectiveness. "I really liked the way in which they measured and published their results," said Robert Nauman, BioPharma Advisors and a judge for the SPA awards. Rx Canada and their client (Eli Lilly Canada) received an innovation award for the Evista Inner Strength Program which ensured that pharmacists followed up with patients 2 weeks after their first intervention. Finally, AstraZeneca received an innovation award for the SERV(TM) Program, which is a platform that allows AZ brands to leverage the sales force to provide messages, tools and programs to physicians toward enhancing medication adherence in their patients.
The prestigious Strategic Patient Adherence (SPA) Awards co-sponsored by CBI and PharmaVoice were presented at the 7th Annual Forum on Patient Compliance, Adherence and Persistency held April 24th in Philadelphia, PA. These awards provided a forum that pays tribute to outstanding programs in the areas of patient compliance/adherence and persistency.
Awards were given to pharmaceutical organizations that met pre-defined
criteria in 5 categories: Innovation, Quality, Measurement, Satisfaction,
Health Outcomes & ROI. Programs that have been deemed exceptional in their
compliance initiatives usually score above 60 points on the judging scale.
Each entry was reviewed by this year's judging panel made up of Grant
Corbett, Founder of Behavior Change Solutions, Inc., Robert Nauman,
Principal at BioPharma Advisors, John Heilman, Senior Commercial Analytics
Manager, New Practice and Corporate Analytics, AstraZeneca, Glenn Gary,
'/>"/>
| SOURCE CBI Research, Inc. Copyright©2008 PR Newswire. All rights reserved |